

KORA SAÚDE PARTICIPAÇÕES S.A.
Publicly Held Company
Corporate Taxpayer's ID 13.270.520/0001-66
Company Registry NIRE 32300031871

MATERIAL FACT

Debt restructuring

KORA SAÚDE PARTICIPAÇÕES S.A. ("Company") (B3: KRSA3), in compliance with the provisions of Law no. 6. 404, of December 15, 1976 and Securities and Exchange Commission ("**CVM**") Resolution No. 44, of August 23, 2021, and in connection with the Material Fact disclosed on October 10, 2024, hereby informs its shareholders and the market in general that it has successfully completed the process of reprofiling its debt, built up over the last few months with the aim of strengthening the Company's capital structure and liquidity ("**Reprofiling**").

The Reprofiling involved the participation of the creditors of the Company's 1st issue of debentures ("KRSA11" and "KRSA21") and the 2nd issue of debentures of Hospital Anchieta S.A. ("**HSPA12**"), a direct subsidiary of the Company, which culminated in the new terms and conditions of these issues, as approved at the respective general meetings of debenture holders held on November 21, 2024.

Additionally, the Company carried out its 2nd issue of debentures, in the total amount of R\$1,951,122,000.00, with the debentures having been issued for public distribution under the automatic distribution registration rite established by CVM Resolution 160/2022, aimed exclusively at Professional Investors, whose respective Closing Announcement was published on this date ("**2nd Debenture Issue**").

The net funds obtained by the Company as a result of the 2nd Issue of Debentures were substantially used to repay the KRSA11, KRSA21 and HSPA12 debentures and a significant part of the Company's bilateral debts ("**Exchange**"). The remainder of the net funds obtained by the Company will be used to strengthen its cash position.

The Company believes that the Reprofiling, with its new payment schedule, and the cash reinforcement will be of great value for the conduct of business in the next cycle.

For further information, please access the documents relating to the Reprofiling, the resolutions and additions under the KRSA11, KRSA21 and HSPA12 debentures, and the offer of the 2nd Debenture Issue, available on the Company's websites (<https://ri.korasaude.com.br/>), the CVM (www.cvm.gov.br) and B3 S.A. - Brasil, Bolsa, Balcão (www.b3.com.br).

Vitória/ES, October 10, 2024.

Elias Leal Lima

Chief Financial and Investor Relations Officer